Vanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting

Rhea-AI Summary

Vanda Pharmaceuticals (NASDAQ: VNDA) announced its participation in the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting in Scottsdale, Arizona, scheduled from May 27-30, 2025. Dr. Sean R. Chadwick from Clinical Development will present a poster titled "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets" during Poster Presentation Session II. The presentation, designated as Poster Number T19, will take place on May 27, 2025.

WASHINGTON, May 27, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, to be held in Scottsdale, Arizona, from May 27 through May 30, 2025.

The following will be presented:

May 27, 2025

Presentation Title: "Pharmacokinetic Results of Single-Dose and Multiple-Dose Bioequivalence Studies of Milsaperidone and Iloperidone Immediate-Release Oral Tablets"
Poster Presentation Session: II
Poster Number: T19
Presenter: Sean R. Chadwick, PhD, Clinical Development

About Bysanti™

Bysanti™ is a new chemical entity that belongs in the class of atypical antipsychotic drugs. If approved, Bysanti™ could be available for sale in the US in 2026. Bysanti™ is believed to achieve its therapeutic effect by interacting with a host of neurotransmitter receptors in the brain, including the alpha-adrenergic receptor, serotonin receptors and dopamine receptors. Exclusivity, including pending patent applications, could extend into the 2040s.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

Corporate Contact:

Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden/Jack Keleher/Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentation-at-2025-ascp-annual-meeting-302465772.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What will Vanda Pharmaceuticals (VNDA) present at the 2025 ASCP Annual Meeting?

Vanda will present a poster on pharmacokinetic results comparing bioequivalence studies of Milsaperidone and Iloperidone immediate-release oral tablets.

When and where is the 2025 ASCP Annual Meeting where VNDA will present?

The ASCP Annual Meeting will be held in Scottsdale, Arizona, from May 27 through May 30, 2025.

Who will present Vanda Pharmaceuticals' research at the 2025 ASCP Meeting?

Dr. Sean R. Chadwick from Clinical Development will present the research as Poster Number T19.

What is the poster number and session for Vanda's presentation at ASCP 2025?

The presentation will be Poster Number T19 during Poster Presentation Session II.